T TITAN PHARMACEUTICALS Logo (WIPO, 06/16/2017)
WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark T TITAN PHARMACEUTICALS was filed as Figurative mark on 06/16/2017 at the World Intellectual Property Organization.
Logodesign (Wiener Klassifikation)
#Quadrilaterals #Different geometrical figures, juxtaposed, joined or intersecting #Colours #Quadrilaterals with inscriptions projecting beyond one or more of the sides thereof #Triangles or lines forming an angle with one or more quadrilaterals #Three predominant colours
| Trademark form | Figurative mark |
| File reference | 1366454 |
| Countries | 
|
| Base trademark |
No. 87278812,
December 22, 2016
|
| Application date | June 16, 2017 |
| Expiration date | June 16, 2027 |
Trademark owner
400 Oyster Point Boulevard, Suite 505
South San Francisco CA 94080
US
South San Francisco CA 94080
US
Trademark representatives
425 Market Street
San Francisco CA 94105
US
goods and services
05
Pharmaceuticals, namely, for the treatment central nervous
disorders, cancer, hematological disorders, endocrine
disorders, metabolic disorders, inflammatory disorders,
gastrointestinal disorders, liver disease, heart disorders,
lung and bronchial disease, blood cardiovascular disease,
circulatory system disease, intestinal disorders, bone
disease, autoimmune disorders and disorders of the immune
systems, infectious disease and enzyme deficiency disease;
implantable delivery systems comprised of sustainable
release drugs for treatment for central nervous disorders
and other serious and life-threatening diseases, cancer,
hematological disorders, endocrine disorders, metabolic
disorders, inflammatory disorders, gastrointestinal
disorders, liver disease, heart disorders, lung and
bronchial disease, blood cardiovascular disease, circulatory
system disease, intestinal disorders, bone disease,
autoimmune disorders and disorders of the immune systems,
infectious disease and enzyme deficiency disease;
pharmaceuticals, namely, implantable drug delivery system
comprised primarily of a polymer-based subdermal matrix
formulation for the sustained release of drugs in the
treatment of opiate addiction; pharmaceuticals, namely,
implantable drug delivery system comprised primarily of a
polymer-based matrix formulation for the sustained release
of drugs in the treatment of central nervous system
disorders and other serious and life-threatening diseases
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| September 14, 2018 | 2018/38 Gaz | CH | Rejection |
| April 19, 2018 | 2018/16 Gaz | JP | Rejection |
| March 2, 2018 | 2018/10 Gaz | EM | Rejection |
| June 16, 2017 | 2017/37 Gaz | US | Registration |
ID: 141366454